| 101 |
30167550 | Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease. | 2016 Dec |
1 |
| 102 |
25025538 | Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment. | 2015 |
1 |
| 103 |
25179732 | Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. | 2015 Jan |
2 |
| 104 |
25351958 | The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases. | 2015 Jan 15 |
2 |
| 105 |
25499760 | Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. | 2015 Feb 26 |
1 |
| 106 |
25526365 | A sensitive and microscale method for drug screening combining affinity probes and single molecule fluorescence correlation spectroscopy. | 2015 Feb 21 |
2 |
| 107 |
25831762 | [Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib]. | 2015 Feb |
1 |
| 108 |
25842192 | Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. | 2015 Sep |
1 |
| 109 |
25889792 | The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. | 2015 Mar 24 |
1 |
| 110 |
25913326 | A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML). | 2015 Aug |
1 |
| 111 |
25996455 | Small-world networks of residue interactions in the Abl kinase complexes with cancer drugs: topology of allosteric communication pathways can determine drug resistance effects. | 2015 Jul |
2 |
| 112 |
26284693 | Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. | 2015 Nov |
1 |
| 113 |
26430722 | Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. | 2015 Oct 2 |
1 |
| 114 |
26473951 | Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release. | 2015 |
1 |
| 115 |
26588899 | Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action. | 2015 Nov 21 |
1 |
| 116 |
23989453 | A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia. | 2014 Jan |
1 |
| 117 |
24143950 | BCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemia. | 2014 Jul |
1 |
| 118 |
24258348 | Ever-advancing chronic myeloid leukemia treatment. | 2014 Feb |
1 |
| 119 |
24311723 | Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). | 2014 Jan 23 |
1 |
| 120 |
24569263 | Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. | 2014 Apr 10 |
1 |
| 121 |
24569990 | Inhibiting tyrosine phosphorylation of protein kinase Cδ (PKCδ) protects the salivary gland from radiation damage. | 2014 Apr 11 |
1 |
| 122 |
24734217 | Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. | 2014 Jan 1 |
1 |
| 123 |
24756784 | Dasatinib. | 2014 |
3 |
| 124 |
24847647 | New resistance mechanisms for small molecule kinase inhibitors of Abl kinase. | 2014 Mar |
1 |
| 125 |
24882272 | Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3. | 2014 Sep |
1 |
| 126 |
24975338 | [Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment]. | 2014 Jun |
1 |
| 127 |
25006277 | Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting. | 2014 Jan |
1 |
| 128 |
25023728 | Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. | 2014 Sep 1 |
1 |
| 129 |
25068103 | Identification of a novel SEPT9-ABL1 fusion gene in a patient with T-cell prolymphocytic leukemia. | 2014 |
1 |
| 130 |
25114223 | Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. | 2014 Aug 26 |
1 |
| 131 |
25173530 | Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer. | 2014 Oct |
1 |
| 132 |
25193862 | Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. | 2014 Sep 15 |
1 |
| 133 |
25198091 | Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin. | 2014 |
1 |
| 134 |
25207766 | Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. | 2014 Sep 11 |
1 |
| 135 |
25284075 | Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway. | 2014 Oct 6 |
2 |
| 136 |
25331939 | Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies. | 2014 Dec |
1 |
| 137 |
25426931 | Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells. | 2014 |
1 |
| 138 |
25501110 | Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase. | 2014 |
4 |
| 139 |
25584281 | Diffuse hypopigmentation followed by hyperpigmentation in an african american woman with hemangiopericytoma treated with dasatinib. | 2014 Nov |
1 |
| 140 |
22392508 | Phase I trial of dasatinib and ixabepilone in patients with solid tumors. | 2013 Feb |
1 |
| 141 |
23053188 | Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. | 2013 Jan |
2 |
| 142 |
23065514 | The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. | 2013 May |
1 |
| 143 |
23065516 | Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells. | 2013 Jun |
1 |
| 144 |
23233201 | PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells. | 2013 Feb |
2 |
| 145 |
23247657 | The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib. | 2013 Mar 21 |
2 |
| 146 |
23299860 | Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. | 2013 May |
2 |
| 147 |
23372106 | Treating chronic myeloid leukemia: improving management through understanding of the patient experience. | 2013 Feb |
2 |
| 148 |
23383600 | Surrogate end points for long-term outcomes in chronic myeloid leukemia. | 2013 Oct |
1 |
| 149 |
23409026 | Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. | 2013 |
2 |
| 150 |
23420553 | Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition. | 2013 May |
1 |